HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Weintraub leaving FDA in July; OTCs to be overseen on acting basis by DeLap.

This article was originally published in The Rose Sheet

Executive Summary

FDA OTC DRUGS DIVISION WILL BE OVERSEEN BY ROBERT DELAP, MD/PhD, who is taking the helm of FDA's Office of Drug Evaluation V, which includes the Division of Over-the-Counter Drug Products, July 3. DeLap will assume the role of acting director following the departure of Office of Drug Evaluation V Director Michael Weintraub, MD. DeLap, currently deputy director of ODE V, will act as director until a permanent replacement is named; he was appointed to the newly created deputy post May 26. DeLap previously was director of FDA's Oncology Drug Products Division.
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS005496

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel